OTCMKTS:BMXMF - bioMérieux Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$94.43
+0 (0.00%)

This chart shows the closing price for BMXMF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New bioMérieux Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMXMF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMXMF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for bioMérieux in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $94.43.

This chart shows the closing price for BMXMF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in bioMérieux. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/22/2021AlphaValueUpgradeReduce
10/27/2021Exane BNP ParibasUpgradeUnderperform ➝ Outperform
6/11/2021Berenberg BankUpgradeSell ➝ Hold
3/1/2021Morgan StanleyReiterated RatingOverweight
2/25/2021Societe GeneraleReiterated RatingBuy
2/19/2021Berenberg BankDowngradeHold ➝ Sell
12/10/2020BNP ParibasDowngradeNeutral ➝ Underperform
12/10/2020Exane BNP ParibasDowngradeNeutral ➝ Underperform
12/9/2020Morgan StanleyInitiated CoverageOverweight
10/23/2020Societe GeneraleUpgradeHold ➝ Buy
9/23/2020Berenberg BankReiterated RatingHold
7/13/2020Societe GeneraleDowngradeBuy ➝ Hold
4/30/2020Berenberg BankReiterated RatingHold
(Data available from 7/6/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/7/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/6/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
bioMérieux logo
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Read More

Today's Range

Now: $94.43
Low: $94.43
High: $94.43

50 Day Range

MA: $94.20
Low: $85.00
High: $105.32

52 Week Range

Now: $94.43
Low: $84.79
High: $148.50

Volume

N/A

Average Volume

82 shs

Market Capitalization

$11.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of bioMérieux?

The following equities research analysts have issued research reports on bioMérieux in the last year: AlphaValue, and Exane BNP Paribas.
View the latest analyst ratings for BMXMF.

What is the current price target for bioMérieux?

0 Wall Street analysts have set twelve-month price targets for bioMérieux in the last year.
View the latest price targets for BMXMF.

What is the current consensus analyst rating for bioMérieux?

bioMérieux currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BMXMF, but not buy more shares or sell existing shares.
View the latest ratings for BMXMF.

How do I contact bioMérieux's investor relations team?

bioMérieux's physical mailing address is 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280. The company's listed phone number is 33-04-78-87-20-00 and its investor relations email address is [email protected] The official website for bioMérieux is www.biomerieux.com. Learn More about contacing bioMérieux investor relations.